5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzylidene]-2,4-thiazolidinedione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzylidene]-2,4-thiazolidinedione
• 英文别名: 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-methoxy)benzylidene]-2,4-thiazolidinedione；(5E)-5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methylidene]-1,3-thiazolidine-2,4-dione
• 化学式: C₂₄H₂₅NO₅S
• 分子量: 439.532
• InChiKey: KHWHTBDGXPHZMC-YBFXNURJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzylidene]-2,4-thiazolidinedione 在 氢气 、 溶剂黄146 作用下， 以 水 、 钯 为溶剂， 生成 曲格列酮
  参考文献：
  名称：

  Benzylidenethiazolidine derivatives and their use for the inhibition

  摘要：

  Benzylidenethiazolidine化合物的化学式（I）：##STR1##[其中R.sup.1，R.sup.2和R.sup.5分别为氢或烷基；R.sup.3和R.sup.4分别为氢、烷基、甲酰基、烷基羰基、芳基羰基、羧基、烷氧羰基、芳氧羰基、羟基、烷基羰氧基、甲酰氧基、芳基羰氧基、可选择取代的烷氧基或卤素；W为亚甲基、羰基或化学式>C.dbd.N--OV的基团，其中V为氢、烷基羰基、芳基羰基或可选择取代的烷基；n为1至3的整数]及其盐具有抑制哺乳动物体内脂质过氧化物形成的能力，因此可用于治疗动脉粥样硬化和其他因脂质过氧化物水平不平衡而引起的疾病和紊乱。它们还可用于制备相应的苯基硫代乙酰胺化合物，其通常具有更强的降糖活性。还提供了制备这些化合物（I）的方法。

  公开号：

  US05387596A1
• 作为产物：
  描述：

  4-((6-((tert-butyldimethylsilyl)oxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzaldehyde 在 哌啶 、 盐酸 、 溶剂黄146 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 4.25h， 生成 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzylidene]-2,4-thiazolidinedione
  参考文献：
  名称：

  Structure–activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium

  摘要：

  Depletion of calcium from the endoplasmic reticulum has shown to affect protein synthesis and cell proliferation. The anticancer effect of troglitazone was reported to be mediated by depletion of intracellular calcium stores resulting in inhibition of translation initiation. The unsaturated form of troglitazone displays similar anticancer properties in vitro. In this letter, we report our findings on the minimum structural requirements for both compounds to retain their calcium release and antiproliferative activities. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.087

文献信息

• Benzylidenethiazolidine derivatives and their use for the inhibition
  申请人：Sankyo Company, Limited

  公开号：US05387596A1

  公开（公告）日：1995-02-07

  Benzylidenethiazolidine compounds of formula (I): ##STR1## [in which R.sup.1, R.sup.2 and R.sup.5 are each hydrogen or alkyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, formyl, alkylcarbonyl, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl, hydroxy, alkylcarbonyloxy, formyloxy, arylcarbonyloxy, optionally substituted alkoxy or halogen; W is methylene, carbonyl or a group of formula >C.dbd.N--OV, wherein V is hydrogen, alkylcarbonyl, arylcarbonyl or optionally substituted alkyl; and n is an integer of from 1 to 3] and salts thereof have the ability to inhibit the formation of lipid peroxide in the mammalian body, and can therefore be used for the treatment of arteriosclerosis and other diseases and disorders arising from an imbalance in the lipid peroxide level. They can also be used for the preparation of the corresponding benzylthiazolidine compounds, which have a generally greater hypoglycemic activity. Processes for the preparation of these compounds of formula (I) are also provided.

  Benzylidenethiazolidine化合物的化学式（I）：##STR1##[其中R.sup.1，R.sup.2和R.sup.5分别为氢或烷基；R.sup.3和R.sup.4分别为氢、烷基、甲酰基、烷基羰基、芳基羰基、羧基、烷氧羰基、芳氧羰基、羟基、烷基羰氧基、甲酰氧基、芳基羰氧基、可选择取代的烷氧基或卤素；W为亚甲基、羰基或化学式>C.dbd.N--OV的基团，其中V为氢、烷基羰基、芳基羰基或可选择取代的烷基；n为1至3的整数]及其盐具有抑制哺乳动物体内脂质过氧化物形成的能力，因此可用于治疗动脉粥样硬化和其他因脂质过氧化物水平不平衡而引起的疾病和紊乱。它们还可用于制备相应的苯基硫代乙酰胺化合物，其通常具有更强的降糖活性。还提供了制备这些化合物（I）的方法。
• Small molecule cyclin D1 ablative agents
  申请人：Chen Ching-Shih

  公开号：US20060252802A1

  公开（公告）日：2006-11-09

  Cyclin D1 ablative agents and methods of using these agents in the treatment of cancers, and particularly breast cancer. Also provided are methods of treating cancer, the method comprising administering a therapeutically effective amount of one of the cyclin D1 ablative agents described herein to a subject in need of such treatment. Also provided are methods of treating cancers comprising using the cyclin D1 ablative agents described herein in combination therapies with existing chemotherapeutic agents.

  细胞周期蛋白 D1 消融制剂和使用这些制剂治疗癌症，特别是乳腺癌的方法。还提供了治疗癌症的方法，该方法包括向需要治疗的受试者施用治疗有效量的本文所述细胞周期蛋白D1消融制剂。还提供了治疗癌症的方法，包括使用本文所述的细胞周期蛋白D1消融剂与现有的化疗药物联合治疗。
• Small molecule Bcl-xL/Bcl-2 binding inhibitors
  申请人：Chen Ching-Shih

  公开号：US20060252801A1

  公开（公告）日：2006-11-09

  Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.

  Bcl-xL/Bcl-2结合抑制剂用于治疗需要此类治疗的受试者的不需要的增殖细胞，包括癌症和癌前病变。还提供了治疗具有不需要的增殖细胞的受试者的方法，包括向需要这种治疗的受试者施用治疗有效量的本文所述的Bcl-xL/Bcl-2结合抑制剂。还提供了防止不需要的增殖细胞（如癌症和癌前病变）在受试者体内增殖的方法，包括向有可能患以不需要的增殖细胞为特征的疾病的受试者施用治疗有效量的本文所述的Bcl-xL/Bcl-2结合抑制剂的步骤。
• SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS
  申请人：Chen Ching-Shih

  公开号：US20100168184A1

  公开（公告）日：2010-07-01

  Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.
• US7566787B2
  申请人：——

  公开号：US7566787B2

  公开（公告）日：2009-07-28